Last reviewed · How we verify
Standard: Dexamethasone
Dexamethasone is a synthetic corticosteroid that functions as a potent anti-inflammatory agent by inhibiting the production of pro-inflammatory cytokines and mediators.
Dexamethasone is a synthetic corticosteroid that functions as a potent anti-inflammatory agent by inhibiting the production of pro-inflammatory cytokines and mediators. Used for Multiple myeloma, Hematological malignancies, Neurological disorders.
At a glance
| Generic name | Standard: Dexamethasone |
|---|---|
| Sponsor | CCTU |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Rheumatology, Neurology |
| Phase | Phase 3 |
Mechanism of action
It achieves this by binding to the glucocorticoid receptor, which then translocates to the nucleus and regulates the expression of genes involved in inflammation. This results in a decrease in the production of pro-inflammatory cytokines and mediators, leading to a reduction in inflammation.
Approved indications
- Multiple myeloma
- Hematological malignancies
- Neurological disorders
- Respiratory diseases
- Inflammatory conditions
Common side effects
- Hyperglycemia
- Hypokalemia
- Nausea
- Vomiting
- Headache
Key clinical trials
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |